Clinical Trials Browser

OTHER × vadimezan × Genitourinary × Clear all

NCT01071928 2015-08-19

Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma

Phase 2 Withdrawn

Carcinoma, Transitional Cell